» Articles » PMID: 35661229

Depression and Anxiety Prevalence in People with Cystic Fibrosis and Their Caregivers: a Systematic Review and Meta-analysis

Overview
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Prevalence of depression and anxiety in people with cystic fibrosis (PwCF) and their caregivers is high, however, results have been inconsistent. This systematic review and meta-analysis aimed to estimate the prevalence of depression and anxiety in PwCF and their caregivers and explore sources of heterogeneity.

Method: MEDLINE, EMBASE, CINAHL plus and PsychINFO databases were searched from inception to January 2021. Studies were included if a specific psychometric tool (PT) to assess depression or anxiety (rather than quality of life) was used and did not involve a transitory patient state. Random-effects models were applied due to high anticipated heterogeneity and Iestimates were calculated. Sources of heterogeneity were explored through subgroup comparisons. The presence of small-study effects was investigated visually using funnel plots and statistically using the Egger test.

Results: A total of 94 articles (48 full-text publications, 46 abstracts) were included. Depression prevalence in adolescents aged 12-18 years (n = 2386), adults (n = 9206) and caregivers (n = 6617) were 18.7% (95% CI 12.8-25.3%, I = 89.2%), 27.2% (95% CI 23.6-31%, I = 90.4%), and 32.8% (95% CI 27.9-37.9%, I = 90.3%), respectively. Anxiety prevalence in adolescents aged 12-18 years (n = 2142) was 26% (95% CI 19.6-33%, I = 86.4%), 28.4% (95% CI 25-31.9%, I = 85%) for adults (n = 8175), and 38.4% (95% CI 30.8-46.2%, I = 94.6%) for caregivers (n = 5931). Prevalence differed by the PT used and study location.

Discussion: This comprehensive analysis found the prevalence of depression and anxiety in PwCF and their caregivers to be high, supporting recommendations for regular screening. Choice of PT significantly influenced prevalence, indicating a need for future studies to identify the optimal PT for each CF population to identify those most at risk.

Citing Articles

Successful Therapy over 12 Months of People with Cystic Fibrosis with Rare Non-phe508del Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Mutations with Elexacaftor/Tezacaftor/Ivacaftor (ETI).

Sutering T, Bode S, Fischer R, Fabricius D Adv Respir Med. 2024; 92(6):559-572.

PMID: 39727500 PMC: 11672886. DOI: 10.3390/arm92060049.


Descriptive epidemiology demonstrating the All of Us database as a versatile resource for the rare and undiagnosed disease community.

Magee D, Kicker S, Thomas A J Am Med Inform Assoc. 2024; 32(3):579-585.

PMID: 39715481 PMC: 11833481. DOI: 10.1093/jamia/ocae241.


Edinburgh postnatal depression scale score elevation in caregivers of infants with cystic fibrosis.

Gillespie M, Jayaram S, Eisner M, Sliemers S, Pasley K, McCoy K Pediatr Pulmonol. 2024; 60(1):e27364.

PMID: 39469979 PMC: 11740653. DOI: 10.1002/ppul.27364.


Amygdalar involvement in respiratory dysfunction.

Trevizan-Bau P, Hayes J, Bolser D, Reznikov L Front Physiol. 2024; 15:1424889.

PMID: 39263625 PMC: 11387172. DOI: 10.3389/fphys.2024.1424889.


Racial inequities and rare variants: Impact on cystic fibrosis diagnosis and treatment.

Wu M, Davis J, Zhao C, Daley T, Oliver K J Clin Transl Endocrinol. 2024; 36:100344.

PMID: 38765466 PMC: 11099334. DOI: 10.1016/j.jcte.2024.100344.


References
1.
Quittner A, Abbott J, Georgiopoulos A, Goldbeck L, Smith B, Hempstead S . International Committee on Mental Health in Cystic Fibrosis: Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus statements for screening and treating depression and anxiety. Thorax. 2015; 71(1):26-34. PMC: 4717439. DOI: 10.1136/thoraxjnl-2015-207488. View

2.
Moher D, Liberati A, Tetzlaff J, Altman D . Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009; 6(7):e1000097. PMC: 2707599. DOI: 10.1371/journal.pmed.1000097. View

3.
Munn Z, Aromataris E, Tufanaru C, Stern C, Porritt K, Farrow J . The development of software to support multiple systematic review types: the Joanna Briggs Institute System for the Unified Management, Assessment and Review of Information (JBI SUMARI). Int J Evid Based Healthc. 2018; 17(1):36-43. DOI: 10.1097/XEB.0000000000000152. View

4.
Gundogdu U, Fis N, Eralp E, Karadag B . Major depression and psychiatric comorbidity in Turkish children and adolescents with cystic fibrosis. Pediatr Pulmonol. 2019; 54(12):1927-1935. DOI: 10.1002/ppul.24492. View

5.
Egger M, Davey Smith G, Schneider M, Minder C . Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997; 315(7109):629-34. PMC: 2127453. DOI: 10.1136/bmj.315.7109.629. View